AKT1 and neoplasm: Further investigations indicated that compound (18) decreased VEGF-induced phosphorylation of Akt, mTOR, MEK1/2, ERK1/2, and p38 MAPK in endothelial cells, and, by inhibiting Akt/mTOR and ERK-dependent pathways, it strongly suppressed tumor cell growth and proliferation.